Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chronic inflammation and cancer.

Emily Shacter1, Sigmund A Weitzman

  • 1Laboratory of Immunology, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892-4555, USA. shacter@cber.fda.gov

Oncology (Williston Park, N.Y.)
|February 28, 2002
PubMed
Summary

Chronic inflammation, driven by infections or irritants, significantly increases cancer risk over time. Understanding its molecular basis, including inflammatory mediators, is key to developing new cancer prevention and treatment strategies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PDA Biosimilars Workshop Report (September 27-28, 2018)-Getting It Right the First Time for Biosimilar Marketing Applications.

PDA journal of pharmaceutical science and technology·2019
Same author

Letter to the Editors.

Journal of periodontology·2018
Same author

Taurine chloramine-induced inactivation of cofilin protein through methionine oxidation.

Free radical biology & medicine·2014
Same author

Mito-tempol and dexrazoxane exhibit cardioprotective and chemotherapeutic effects through specific protein oxidation and autophagy in a syngeneic breast tumor preclinical model.

PloS one·2013
Same author

Chronic inflammation and cancer: the role of the mitochondria.

Oncology (Williston Park, N.Y.)·2011
Same author

The antioxidant transcription factor Nrf2 negatively regulates autophagy and growth arrest induced by the anticancer redox agent mitoquinone.

The Journal of biological chemistry·2010

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Chronic inflammation is a known risk factor for cancer development.
  • Conditions like inflammatory bowel disease are linked to increased colon cancer risk.
  • Inflammation can persist due to infections, chemical irritants, or foreign particles.

Purpose of the Study:

  • To review the underlying causes of the association between chronic inflammation and cancer.
  • To elucidate the molecular mechanisms by which inflammation promotes carcinogenesis.
  • To highlight the role of specific inflammatory mediators in cancer development.

Main Methods:

  • Literature review of studies investigating inflammation and cancer.
  • Analysis of molecular pathways linking inflammation to neoplasia.

Related Experiment Videos

  • Discussion of key inflammatory mediators involved in carcinogenesis.

    • Main Results:

    • Inflammatory mediators promote cancer by inducing mutations, adaptive responses, and resistance to apoptosis.
    • Chronic inflammation creates a microenvironment that favors tumor growth, including stimulating angiogenesis.
    • Reactive oxygen/nitrogen intermediates, prostaglandins, and cytokines are key contributors to inflammation-associated cancer.

    Conclusions:

    • A comprehensive understanding of inflammation's role in cancer is crucial.
    • Targeting molecular pathways involved in inflammation-associated neoplasia offers novel therapeutic and preventive strategies.
    • Further research into the molecular basis of inflammation-driven cancer can lead to improved patient outcomes.